Dashboard
The company has declared positive results in Mar'2025 after 4 consecutive negative quarters
- NET SALES(Q) At CNY 174.75 MM has Grown at 42.66%
- PRE-TAX PROFIT(Q) At CNY 55.56 MM has Grown at 176.83%
- NET PROFIT(Q) At CNY 46.83 MM has Grown at 179.72%
With ROE of 3.51%, it has a attractive valuation with a 0.33 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 727 Million (Micro Cap)
10.00
NA
1.12%
-0.57
3.51%
0.33
Total Returns (Price + Dividend) 
Kingchem (Liaoning) Life Science Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News

Kingchem Reports Strong Sales Growth and Improved Profitability Amid Cost Reductions
Kingchem (Liaoning) Life Science Co., Ltd. has recently adjusted its evaluation, reflecting significant changes in its financial performance. The company reported substantial growth in net sales and profits, alongside a notable decrease in raw material costs and improved inventory turnover, highlighting its evolving market position.
Read More Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot
Shareholding Compare (%holding) 
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
YoY Growth in quarter ended Jun 2025 is 24.65% vs -37.07% in Jun 2024
YoY Growth in quarter ended Jun 2025 is 57.79% vs -78.37% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is -35.48% vs 6.95% in Dec 2023
YoY Growth in year ended Dec 2024 is -77.76% vs 7.49% in Dec 2023






